0001841258 false 00-0000000 00000 NASDAQ NASDAQ NASDAQ true 0001841258 2021-11-22 2021-11-22 0001841258 us-gaap:CommonClassAMember 2021-11-22 2021-11-22 0001841258 us-gaap:WarrantMember 2021-11-22 2021-11-22 0001841258 us-gaap:CapitalUnitsMember 2021-11-22 2021-11-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

November 22, 2021

 

European Biotech Acquisition Corp.

(Exact Name of Registrant as Specified in its Charter)

 

Cayman Islands   001-40211   N/A

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

Johannes Vermeerplein 9

1071 DV Amsterdam, Netherlands

 

N/A

(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 31 (0) 20 664 55 00

 

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A ordinary shares, par value $0.0001 per share   EBAC   The Nasdaq Capital Market
Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50   EBACW   The Nasdaq Capital Market
Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant   EBACU   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

 

European Biotech Acquisition Corp. (the “Company”) previously presented a portion of its shares of Class A ordinary shares subject to redemption (the “Class A Shares”) as permanent equity because the Company’s certificate of incorporation does not permit redemptions of Class A Shares that would cause the Company’s net tangible assets to be less than $5,000,001. After discussion and evaluation, including with the Company’s independent registered public accounting firm, Marcum LLP (“Marcum”), the Company has concluded that all Class A Shares should be classified as temporary equity because such shares can be redeemed or become redeemable subject to the occurrence of events outside the Company’s sole control.

 

On November 22, 2021, the Audit Committee of the Board of Directors of the Company concluded, after discussion with the Company’s management, that the Company’s audited balance sheet as of March 18, 2021 filed as Exhibit 99.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 24, 2021 and its balance sheets as of March 31, 2021 and June 30, 2021 included in its Quarterly Reports on Form 10-Q filed on June 22, 2021 and August 18, 2021, respectively, should no longer be relied upon due to changes required to classification of temporary equity and permanent equity described above. The Company has reflected this reclassification of equity in its upcoming Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 to be filed with the SEC and plans to amend the Current Report on Form 8-K filed on March 24, 2021 to file the revised audited balance sheet as of March 18, 2021.

 

The Company’s management has concluded that in light of the classification error described above, a material weakness exists in the Company’s internal control over financial reporting and that the Company’s disclosure controls and procedures were not effective.

 

The Company does not expect any of the above changes will have any impact on its cash position and cash held in the trust account.

 

In addition, the audit report of Marcum included in Exhibit 99.1 to the Company’s Form 8-K filed on March 24, 2021 should no longer be relied upon.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 22, 2021

 

  EUROPEAN BIOTECH ACQUISITION CORP.
   
   
  By: /s/ Koen Sintnicolaas
    Koen Sintnicolaas
    Chief Financial Officer

 

European Biotech Acquisi... (NASDAQ:EBAC)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more European Biotech Acquisi... Charts.
European Biotech Acquisi... (NASDAQ:EBAC)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more European Biotech Acquisi... Charts.